Last reviewed · How we verify
Concerta — Competitive Intelligence Brief
marketed
Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Concerta (Concerta) — Lei Lei, MD.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Concerta TARGET | Concerta | Lei Lei, MD | marketed | Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor | ||
| Ritalin | methylphenidate | Novartis | marketed | Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Ritalin · 8840924 · Formulation · US
- — Ritalin · 9072680 · Formulation · US
- — Ritalin · 9089496 · Formulation · US
- — Ritalin · 11166947 · Method of Use · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Concerta — Competitive Intelligence Brief. https://druglandscape.com/ci/concerta. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab